Abstract
Report description
The Bigpharma Partnering Agreements provides comprehensive and unprecedented
access to the partnering agreements entered into by the worlds leading fifty
biopharma companies.
Understanding the flexibility of a prospective partner' s negiotated deals
terms provides critical insight into the negotiation process in termsof what
you can expect to achieve during the negotiation of terms. Whilst many smaller
companies will be seeking details of the payments clauses, the devil is in the
detail in terms of how payments are triggered - contract documents provide
this insight where press releases and databases do not.
This report contains over 1,200 links to online copies of actual contract
documents as submitted to the Securities Exchange Commission by bigpharma and
their partners.
Contract documents provide the answers to numerous questions about a
prospective partner' s flexibility on a wide range of important issues, many of
which will have a significant impact on each party' s ability to derive value
from the deal.
The initial chapters of this report provide an orientation of bigpharma' s
dealmaking and business activities. Chapter 1 provides an introduction to the
report, whilst chapter 2 lists the top 50 leading biopharma companies based on
2006 pharmaceutical revenues. Chapter 3 analyses the most active dealmakers in
2005 and 2006 in M&A and partnering deals announced, whilst chapter 4 analyzes
the top deals of 2005-6 according to reported deal size.
The main body of the report is provided in chapter 5. Each of the top 50
bigpharma companies is provided with a brief summary followed by a
comprehensive listing of contract documents available in the public domain.
The listing is sorted by deal type - therefore co-promotion deals are listed
separately to licensing, M&A and supply deals, and so on.
| 
View Cart
